SEC Comment Letter for NYMOX PHARMACEUTICAL CORP (NYMXF) (CIK 0001018735) (NYMXF) — Apr 4, 2022
NYMOX PHARMACEUTICAL CORP (NYMXF) (CIK 0001018735)
Date: April 4, 2022 · CIK: 0001018735 · Accession: 0000000000-22-003616
AI Filing Summary & Sentiment
File numbers found in text: 333-263932
Letter
United States securities and exchange commission logo April 4, 2022 Paul Averback Chief Executive Officer and President Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, The Bahamas Re:Nymox Pharmaceutical Corporation Registration Statement on Form F-3 Filed March 29, 2022 File No. 333-263932 Dear Dr. Averback: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard Cutler, Esq.
Show Raw Text
United States securities and exchange commission logo
April 4, 2022
Paul Averback
Chief Executive Officer and President
Nymox Pharmaceutical Corporation
Bay & Deveaux Streets
Nassau, The Bahamas
Re:Nymox Pharmaceutical Corporation
Registration Statement on Form F-3
Filed March 29, 2022
File No. 333-263932
Dear Dr. Averback:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Richard Cutler, Esq.